Edition:
United Kingdom

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

1.05USD
23 Feb 2018
Change (% chg)

$0.08 (+8.35%)
Prev Close
$0.97
Open
$0.99
Day's High
$1.07
Day's Low
$0.96
Volume
37,652
Avg. Vol
138,008
52-wk High
$5.20
52-wk Low
$0.78

Chart for

About

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $19.05
Shares Outstanding(Mil.): 21.55
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 8.49 16.60
EPS (TTM): -- -- --
ROI: -- 16.30 10.66
ROE: -- 19.56 14.30

BRIEF-Delmar Pharmaceuticals Q2 Loss Per Share $0.14

* DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

14 Feb 2018

BRIEF-DelMar Pharmaceuticals Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma

* DELMAR PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR VAL-083 IN RECURRENT GLIOBLASTOMA

26 Dec 2017

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage:

16 Nov 2017

BRIEF-Delmar Pharmaceuticals names Saiid Zarrabian interim CEO

* Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer

07 Nov 2017

BRIEF-DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6

* DelMar Pharmaceuticals Inc CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing Source text: (http://bit.ly/2kDnPBr) Further company coverage:

10 Oct 2017

BRIEF-DelMar Pharmaceuticals announces $10 million registered direct offering

* Announces $10 million registered direct offering priced at-the-market

20 Sep 2017

BRIEF-Delmar Pharmaceuticals receives IND allowance from FDA

* Delmar Pharmaceuticals receives IND allowance from FDA to initiate clinical trials of VAL-083 for the treatment of ovarian cancer Source text for Eikon: Further company coverage:

18 Sep 2017

BRIEF-Delmar Pharmaceuticals initiates phase 2 clinical trial

* Delmar Pharmaceuticals initiates phase 2 clinical trial in newly diagnosed MGMT-unmethylated glioblastoma multiforme

11 Sep 2017

Competitors

  Price Chg
Gilead Sciences, Inc. (GILD.OQ) $80.91 +1.51
Celgene Corporation (CELG.OQ) $95.61 +1.83
Exelixis, Inc. (EXEL.OQ) $29.51 +0.41

Earnings vs. Estimates